The patent for Daraprim had expired , but no generic version was available . The Turing -- Impax deal included the condition that Impax remove the drug from regular wholesalers and pharmacies , and so in June 2015 , two months before the sale to Turing was announced , Impax switched to tightly controlled distribution . In keeping with its strategy for pricing in the face of limited competition ( see above ) , Turing maintained the closed distribution . The New York Times noted that the deal `` made sense only if Turing planned to raise the price of the drug substantially . ''